Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

12.32
+0.20001.65%
Pre-market: 12.320.00000.00%04:00 EDT
Volume:2.20M
Turnover:26.96M
Market Cap:950.15M
PE:5.82
High:12.50
Open:12.10
Low:11.93
Close:12.12
52wk High:17.29
52wk Low:5.70
Shares:77.12M
Float Shares:69.58M
Volume Ratio:2.23
T/O Rate:3.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.12
EPS(LYR):1.87
ROE:94.62%
ROA:1.82%
PB:4.39
PE(LYR):6.59

Loading ...

Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China

TIPRANKS
·
Aug 21

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Stock News
·
Aug 21

PagerDuty is Maintained at Buy by Truist Securities

Dow Jones
·
Aug 21

Truist Raises Price Target on PagerDuty to $13 From $11, Keeps Buy Rating

MT Newswires Live
·
Aug 20

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Drug for Liver Cancer in China

TIPRANKS
·
Aug 19

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

GlobeNewswire
·
Aug 18

PagerDuty is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 14

Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Dow Jones
·
Aug 14

RBC Capital Sticks to Its Hold Rating for PagerDuty (PD)

TIPRANKS
·
Aug 14

Press Release: PagerDuty to Report Second Quarter Fiscal Year 2027 Results on August 27, 2026

Dow Jones
·
Aug 14

PagerDuty to Report Fiscal Q2 Results After Market Close

Reuters
·
Aug 14

Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 13

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Stock News
·
Aug 12

BTIG Reiterates Buy on PIKTOR as New PK/PD Data De-Risk Development and Support Unchanged $55 Price Target

TIPRANKS
·
Aug 11

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 11

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

GlobeNewswire
·
Aug 11

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Dow Jones
·
Aug 08

Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Dow Jones
·
Aug 07

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 07